VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Business Wire3 天
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Medindia3 天
Neuropathy: Persistent Nerve Pain Affects 40% of Cancer Patients on Chemotherapy
Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...
phillyvoice.com4 天
Chemotherapy often leaves cancer patients with chronic nerve pain
Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...
Many cancer patients experience nerve pain from chemo
Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.
Promising Potential of BridgeBio Pharma’s Attruby Fuels Buy Recommendation
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on BBIO stock, giving a Buy rating on January 14.Invest with Confidence: ...
healthday4 天
Chemo Causes Nerve Pain For Many Cancer Patients
Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence rev ...
News Medical4 天
Chemotherapy linked to persistent nerve pain in 4 in 10 cancer patients
Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...